U.S. Capital Markets Stock News

Founder led companies can give you something that is hard to measure but easy to value: leaders with skin in the game who are building long term legacies rather than chasing the next quarter. With global growth signals improving in several developed markets, inflation generally easing in key regions and central banks moving toward steadier policy paths, many investors are looking for management teams that stay focused through economic cycles. This Founder Led Companies screener narrows that...

Zai Lab recently reported that the U.S. FDA granted Orphan Drug Designation to its DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan (Zoci), for treating neuroendocrine carcinomas, a group of aggressive cancers with limited options. This second orphan designation, following a similar decision in Europe, underlines Zoci’s potential as a first-in-class therapy in a difficult tumor type. We’ll now examine how this new Orphan Drug Designation for Zoci could influence Zai Lab’s...

Alphabet’s surprise AI shakeup has put fresh attention on where leadership and talent sit inside the sector. Jeff Dean and Sanjay Ghemawat are leaving Google to launch a new AI company backed by Alphabet. Demis Hassabis is moving into a chairman and chief scientist role, and Koray Kavukcuoglu is stepping up to run Google’s AI unit and oversee Gemini 4. Alphabet stock fell about 4% after the news. For investors, that kind of disruption can reshape expectations. This article walks through 3 AI...

BETA Technologies (BETA) drew fresh investor attention after announcing plans to expand its financing relationship with the Export Import Bank of the United States, with the potential to secure up to $1b in net funding. See our latest analysis for BETA Technologies. The EXIM financing headlines come after a sharp shift in sentiment around BETA Technologies, with the 1 day share price return of 13.2% and 7 day share price return of 19.5% contrasting with a year to date share price return that...

Symbotic (SYM) heads into its upcoming quarterly earnings report with investor attention on expectations for $0.12 in earnings per share and US$714.76 million in revenue, alongside forecast growth across key warehouse automation segments. See our latest analysis for Symbotic. At a share price of US$47.46, Symbotic has seen a 17.65% 7 day share price return but remains down 26.84% year to date, while the 5 year total shareholder return is about 4x. This indicates short term volatility...

Chemron (CVX) is back in focus after reporting second quarter 2026 results that materially reshaped its income statement. Revenue reached US$70.1b, net income was US$12.1b, and diluted EPS from continuing operations was US$6.11. See our latest analysis for Chevron. Chemron's share price has reacted strongly to the Q2 earnings and dividend news, with a 30 day share price return of 12.53% and a year to date share price return of 22.13%. Over the past year, total shareholder return of 29.62% and...

Why Tyra Biosciences Stock Is Back in Focus After Q2 Results Tyra Biosciences (TYRA) moved into the spotlight after reporting second quarter 2026 results, with a wider net loss and updated timelines for key clinical readouts that could influence how investors view its development pipeline. See our latest analysis for Tyra Biosciences. The second quarter update has arrived during a period where Tyra Biosciences has experienced firm share price momentum, with a 1-month share price return of...

In early August 2026, Keurig Dr Pepper was expected by Wall Street analysts to report past-quarter earnings of US$0.55 per share and revenue of US$7.17 billion, with forecasts also highlighting growth in U.S. Refreshment Beverages and international sales. Analysts also pointed to the integration of the recently acquired JDE Peet's business as a key factor, with potential synergies and international expansion efforts seen as important supports for the company’s performance amid inflation and...

The Cigna Group reported its second-quarter 2026 results, with revenue rising to US$71.67 billion and net income to US$1.66 billion, alongside continued share repurchases under its multiyear buyback program. Despite this growth, recent analyst downgrades have drawn attention to regulatory pressures and uncertainty around Cigna’s pharmacy benefit management operations and business portfolio review. Next, we’ll examine how solid quarterly earnings but heightened PBM and regulatory concerns may...

Tuya Smart recently launched Tuya AI Coding, an AI-native no-code platform that lets non-technical users create and deploy AI-powered lifestyle applications via simple natural-language prompts, fully integrated with Tuya’s global AI+IoT stack and device ecosystem. The ability for Tuya AI Coding to auto-generate full back-end architectures and connect apps to more than 100,000 supported devices could significantly deepen engagement across Tuya’s AI Home ecosystem. Next, we’ll examine how Tuya...

Tennessee completed a statewide cloud migration of its Enterprise Assessment & Tax solution with Tyler Technologies (NYSE:TYL). The project supports nearly 800 users in the Comptroller of the Treasury, Division of Property Assessments. The deployment runs on Amazon Web Services infrastructure and is focused on long term SaaS delivery. The transition is described as one of the largest and most significant statewide cloud moves for this type of system. This Tennessee project places Tyler...

Summit Therapeutics (SMMT) is back in focus after expanding its ivonescimab program with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration with Arcus Biosciences. See our latest analysis for Summit Therapeutics. The latest ivonescimab updates come after a period where Summit Therapeutics’ share price has been volatile. The 1-year total shareholder return declined 51.75%, and the 3-year total shareholder return was very...

Goodyear Tire & Rubber has seen its share price fall 57.5% over the past five years, yet the stock currently screens as cheap on several valuation checks, which puts the recent weakness in a different light for investors looking at the current price. The share price decline of 57.5% over five years points to a company that the market has been cautious on for an extended period, which can sometimes leave valuations disconnected from underlying fundamentals. The planned closure of the...

CME Group stock has delivered a 55.1% gain over the past five years, yet current valuation checks and pricing signals suggest the shares may now sit closer to fair value rather than being a clear bargain. Recent product launches and record activity in key contracts are drawing attention, while the intrinsic value estimate and market multiples offer a more restrained read on potential upside. A 55.1% return over five years points to solid long term wealth creation, which raises the bar for...

Aramark (ARMK) shares are in focus after the company confirmed a quarterly dividend of $0.12 per share and announced a new long-term campus dining partnership with the University of Colorado Colorado Springs. See our latest analysis for Aramark. At a share price of $56.22, Aramark has seen short term momentum ease with the 7 day share price return down 2.06%, although the 90 day share price return of 22.80% and 5 year total shareholder return of 141.27% show a much stronger longer term...

Motorola Solutions stock has delivered a 104.5% return over the past 5 years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a premium rather than a clear bargain. Over the last 5 years, Motorola Solutions has returned 104.5%. This puts recent buyers in profit and raises the bar for what needs to happen next to justify the current share price. Expectations around ongoing demand for Motorola Solutions' mission...

ONE Gas (OGS) shares are in focus after the company reported second quarter 2026 results, which showed higher net income and earnings per share on lower sales, alongside an affirmed quarterly dividend of $0.68 per share. See our latest analysis for ONE Gas. ONE Gas shares recently moved lower in the short term, with the 7 day share price return down 4.18% and the 90 day share price return down 10.08%. At the same time, the 1 year total shareholder return of 10.07% and 5 year total shareholder...

CCC Intelligent Solutions Holdings (CCC) drew fresh investor attention after reporting second quarter and half year 2026 results along with new revenue guidance for the third quarter and full year. See our latest analysis for CCC Intelligent Solutions Holdings. The earnings release and fresh guidance have come after a strong short term rebound in CCC Intelligent Solutions Holdings, with a 30 day share price return of 13.44% and a 90 day gain of 23.63%. However, the share price is still down...

KBR (KBR) recently highlighted a record backlog in its Sustainable Technology Solutions segment, reaffirmed full year 2026 revenue guidance, and advanced plans to spin off Mission Technologies as Trinzic with designated leadership in place. See our latest analysis for KBR. At a share price of US$37.83, KBR has seen a 2.0% 1 day share price return and a 7.8% 90 day share price return, while the 1 year total shareholder return has declined 22.6%. This suggests that short term momentum has...

After a three year stretch where Novo Nordisk stock has declined 50.5%, the valuation picture now looks more supportive than the share price performance suggests, helped by a strong set of value checks even as recent news has weighed on sentiment. The 50.5% fall over three years has reset expectations and leaves investors asking whether the current price already reflects concerns around the business. The failed ZEUS trial for ziltivekimab may cap confidence in Novo Nordisk's pipeline driven...

Fresh tariffs, legal challenges and questions over trade rules are reshaping the outlook for smaller U.S. companies that rely on imported inputs. For investors, this creates both risk and potential opportunity as tariffs of 10% and 12.5% on goods from 60 trading partners feed into costs, pricing power and margins. This article focuses on three U.S. small cap stocks that appear positioned to be positively exposed to the current tariff dispute. By the end, you will have a clearer view of how...

Recent leadership changes at Covista (CVSA) are drawing fresh attention to the stock, after the company created a new Performance Acceleration Office and reshaped responsibilities across its Medical and Veterinary segment. See our latest analysis for Covista. Covista’s recent leadership reshuffle comes as the stock trades at US$129.89, with a 1-day share price return of 1.88% and a 90-day share price return of 12.64%, alongside a 3-year total shareholder return of 190.91% that points to...

Macerich (MAC) is back in focus after reporting second quarter 2026 funds from operations and revenue that topped consensus estimates, alongside a reaffirmed quarterly dividend of $0.17 per common share. See our latest analysis for Macerich. At a recent share price of US$25.62, Macerich has given investors a strong year to date share price return of 38.34%, backed by a 55.04% total shareholder return over the past year and a 126.38% total shareholder return over three years. This points to...

NCR Voyix stock has fallen sharply over the past several years, yet the current market multiples still suggest the shares may be pricing in a lot of optimism. With a mixed valuation score and a long period of weak returns, investors are left weighing whether the current price offers enough compensation for the risks. NCR Voyix has delivered a decline of 65.5% over the past 5 years, which points to a long stretch where shareholders have not been rewarded. Future cash generation from NCR...